The commercial viability of a biotech outfit’s pipeline can often determine the future path of the share price. Irrespective of the past performance, if a company cannot innovate, it will witness its competitive position erode, leading to an inevitable decline in revenue. The latest setback from the clinical labs continues to support a bearish stance on Amgen.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!